Treating MS without continuous immunosuppression: an interview with Luciano Rossetti.
Luciano Rossetti, MD, Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany speaks to Laura Dormer, Commissioning Editor Luciano Rossetti, MD, is Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany, and a member of the Healthcare Executive Committee. As Global Head of R&D, Rossetti leads the strategy for Merck KGaA, Darmstadt, Germany's discovery and development efforts in healthcare. He joined Merck KGaA in July 2014, and has since led the acceleration of several key programs through the pipeline and advanced the innovation of Merck KGaA's discovery teams into development. Under his leadership, R&D has been transformed, with significant potential to deliver the scientific, clinical, regulatory and medical excellence of its teams to patients in need. Before joining Merck KGaA, he served as Senior Vice President, responsible for Global Scientific Strategy and Late Stage Development at Merck Sharp & Dohme, or MSD. In the latter position, he was responsible for clinical development from Phase II to V across all therapeutic areas. Prior to joining MSD in 2006, he spent 18 years in academia during which he had considerable involvement with the pharmaceutical industry in both discovery and development. In his latest assignment, he was Professor of Medicine and led the Diabetes Research & Training Center at the Albert Einstein College of Medicine. He has authored more than 150 peer-reviewed scientific journal articles. He is a Post-Doctoral Fellow of Rome University Medical School and of Yale University Medical School. He holds a Doctorate in Medicine from the Trieste University Medical School, Italy.